Literature DB >> 17603808

Differential modulation of a 40 kDa catecholamine regulated protein in the core and shell subcompartments of the nucleus accumbens following chronic quinpirole and haloperidol administration in the rat.

Joseph Gabriele1, Nancy Thomas, Sevil N-Marandi, Ram Mishra.   

Abstract

Past reports have shown dopamine (DA) D2/D3 receptor agonist quinpirole (QNP) and the DA D2 receptor antagonist, haloperidol (HAL) display a significant increase in expression of catecholamine regulated protein (CRP40) in the nucleus accumbens (NAcc) and the striatum, respectively. The present study investigated the in vivo effects of QNP and HAL on CRP40 protein levels within the core and shell subcompartments of the NAcc. As significant homology exists between CRP40 and Hsp70/Hsc70, parallel studies with inducible Hsp70 and constitutive Hsc70 were conducted to establish the specificity with respect to QNP on Hsp70 and CRP40. Results demonstrated that CRP40 protein was significantly expressed in the shell relative to the core region of NAcc following chronic QNP (+16.28%+/-0.42%, P<0.05) and CRP40 protein was significantly expressed in the core vs. the shell following chronic HAL (+36.02%+/-0.75%, P<0.05). There was no significant change in Hsp70 protein levels following chronic QNP or HAL administration. The results demonstrated selective modulation of CRP40 within NAcc by QNP and HAL treatment, without affecting Hsp70. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17603808     DOI: 10.1002/syn.20435

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  1 in total

1.  Cloning, characterization, and functional studies of a human 40-kDa catecholamine-regulated protein: implications in central nervous system disorders.

Authors:  Joseph Gabriele; Giuseppe F Pontoriero; Nancy Thomas; Christy A Thomson; Kevin Skoblenick; Zdenek B Pristupa; Ram K Mishra
Journal:  Cell Stress Chaperones       Date:  2009-03-12       Impact factor: 3.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.